Precision Weight Loss
Tirzepatide Sublingual Drops
Tirzepatide as liquid drops held under the tongue, for people who would rather not inject.
Browse freely. To purchase medication, you’ll enroll in membership and complete a clinician review. Medication is charged separately and is prescribed only when clinically appropriate.
Availability & pricing
Availability and pricing depend on your state.
Not available to purchase yet
Choose your state to see current availability and pricing.
Check another state or optionMeet Tirzepatide Sublingual Drops
How it works
A dual agonist: it activates both the GIP and the GLP-1 receptor, where semaglutide acts on GLP-1 alone. Both are gut hormones released after eating. Whether acting on two pathways rather than one matters for a given person is a clinical question, not a marketing one.
What to expect
Gradual weight change beginning during titration. Nausea, fullness and constipation are common early and usually settle as the dose stabilises. Head-to-head trial data suggests greater average weight reduction than semaglutide, at a higher price and with the same class side effects.
From your clinician’s notes
The same dual-receptor active ingredient as the injection — GIP and GLP-1 — as a liquid you measure with a dropper and hold under your tongue before swallowing. Your clinician sets the number of drops and how often. That will not be once a week; sublingual dosing runs on a shorter cycle than the injection. Worth knowing before you choose it: how much gets absorbed under the tongue varies more between people than an injection does, so expect your clinician to adjust early on. The upside is that there is no needle and nothing to reconstitute. Included with your $149 monthly membership: your starter lab panel, one-on-one health coaching, 24/7 clinician access, and the member portal. Billed separately: the medication, monthly, plus shipping. Nothing is charged for medication until a clinician has approved it and the pharmacy has accepted the order. Compounded by a licensed 503A pharmacy, not a manufactured brand-name product. Prescription required. Applying does not mean it will be prescribed.
Uses and regulatory status
Chronic weight management alongside a change in diet and physical activity, in adults who meet the clinical criteria.
Tirzepatide is FDA-approved for chronic weight management. The preparation dispensed here is compounded by a licensed 503A pharmacy and is NOT an FDA-approved finished product; compounded preparations are not reviewed by the FDA for safety, effectiveness or manufacturing quality.
Chronic weight management is an FDA-approved indication for this active ingredient. The indication is approved; this compounded formulation is not itself an approved product.
Safety & monitoring
Important safety information
Contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, and in pregnancy. Uncommon but serious risks include pancreatitis and gallbladder disease. The same lean-mass caution applies as to any rapid weight loss.
Monitoring
Weight and waist at each check-in, blood pressure, and metabolic labs including HbA1c and lipids. Lean mass is tracked deliberately. Severe or persistent abdominal pain is reported the same day.
About this form
Administration, storage, evidence limits, formulation
- Administration
- Measure the drops your clinician specifies and hold them under your tongue for the stated time before swallowing. Holding is the mechanism. Avoid eating or drinking immediately afterwards. Not a weekly schedule — follow the one you are given.
- Storage
- Refrigerate at 2-8 degrees C unless the pharmacy label says otherwise; follow the label. Upright, tightly closed, away from light, discarded at the pharmacy's beyond-use date. Keep out of reach of children.
- Evidence limits
- Sublingual tirzepatide has no published controlled trial and no established bioavailability figure. Absorption varies more between people than injection does. Dosing here is inferred rather than measured, and expect early adjustment.
- Formulation
- Prepared by a licensed 503A compounding pharmacy (Strive) with added ingredients; not the FDA-approved finished product.
Compounded by a licensed 503A pharmacy. This is NOT an FDA-approved finished product: compounded preparations are not reviewed by the FDA for safety, effectiveness or manufacturing quality, and it is not interchangeable with the brand-name product. It also contains added ingredients not present in the approved formulation.
Medication guide
Discovery and background
GIP was the first incretin hormone identified, in the early 1970s, but on its own it looked disappointing for diabetes and was largely set aside for decades. The insight behind tirzepatide was that GIP and GLP-1 together behave differently from either alone. A single molecule engineered to hit both receptors turned out to outperform GLP-1 agonism by itself — reviving a hormone the field had written off.
Evidence
SURMOUNT-1 (NEJM 2022) randomised 2,539 adults with obesity or overweight without diabetes and reported dose-dependent weight reduction substantially greater than placebo over 72 weeks. Later head-to-head work against semaglutide favoured tirzepatide on average weight change. IMPORTANT LIMIT: those trials studied the FDA-approved product, not a compounded preparation. No trial has tested what is dispensed here.
Risks
Gastrointestinal effects are common and dose-related, and are the usual reason for stopping. Pancreatitis and gallbladder disease are uncommon but serious. Hypoglycaemia risk rises sharply in combination with insulin or a sulfonylurea. Lean mass loss and post-discontinuation weight regain apply here exactly as they do to semaglutide.
Interactions
Delayed gastric emptying can alter absorption of other oral medicines. Doses of insulin or sulfonylureas usually need reducing. Oral contraceptive absorption can be affected around dose escalation — if that applies to you, ask specifically, because it is easy to miss.
Frequently asked questions
Is tirzepatide better than semaglutide?
On average, trials show greater weight reduction with tirzepatide. Average is not you: side effect tolerance, cost, and what your labs show all matter, and some people do better on semaglutide. This is a conversation with your clinician rather than a ranking.
Why does it cost more?
The drug itself costs us more, and we price it separately rather than folding both into one tier. You can see the difference, which is the point.
What happens if I stop?
Weight regain after discontinuation is common and well documented. Your plan should say what happens when you stop, from the beginning.
Does the dual mechanism cause different side effects?
The side effect profile is broadly the class profile — mostly gastrointestinal, mostly early, mostly settling. There is no evidence that acting on GIP as well makes it meaningfully worse tolerated.
References
- FDA — Compounding and the FDA: Questions and Answers — published Feb 1, 2023; accessed Sep 2, 2026
- ZEPBOUND (tirzepatide) injection — FDA prescribing information — published Nov 8, 2023; accessed Sep 2, 2026
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216 — published Jul 21, 2022; accessed Sep 2, 2026
- FDA — Compounding and the FDA: Questions and Answers — published Feb 1, 2023; accessed Sep 2, 2026
- USP General Chapter <795> Pharmaceutical Compounding — Nonsterile Preparations — published Nov 1, 2023; accessed Sep 2, 2026
Ready when you are.
Check another state or optionBrowse freely. To purchase medication, you’ll enroll in membership and complete a clinician review. Medication is charged separately and is prescribed only when clinically appropriate.
Compounded by a licensed 503A pharmacy. This is NOT an FDA-approved finished product: compounded preparations are not reviewed by the FDA for safety, effectiveness or manufacturing quality, and it is not interchangeable with the brand-name product. It also contains added ingredients not present in the approved formulation.
Chronic weight management is an FDA-approved indication for this active ingredient. The indication is approved; this compounded formulation is not itself an approved product.